Biocartis Group NV
Develops and commercializes an automated molecular diagnostics platform for oncology.
BCART | BR
Overview
Corporate Details
- ISIN(s):
- BE0974281132 (+1 more)
- LEI:
- 549300J4HOJL5KG8HY54
- Country:
- Belgium
- Address:
- GENERAAL DE WITTELAAN 11 BOÎTE B, 2800 MECHELEN
- Website:
- https://www.biocartis.com/en
- Sector:
- Manufacturing
Description
Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-04-13 07:00 |
AGM EGM 2021 - Outstanding shares and voting rights (DUT) (final).pdf
|
Dutch | 121.8 KB | ||
| 2021-04-13 07:00 |
Biocartis Group NV_Audit report Stat (DUT)_SIGNED.pdf
|
Dutch | 569.6 KB | ||
| 2021-04-13 07:00 |
Biocartis Group NV_Audit report Conso (DUT)_SIGNED.pdf
|
Dutch | 613.7 KB | ||
| 2021-04-13 07:00 |
AGM EGM 2021 - Board Report 7199 BCCA (ENG) (final)_SIGNED.pdf
|
English | 327.5 KB | ||
| 2021-04-13 07:00 |
AGM EGM 2021 - Remuneration Policy (NL) (final).pdf
|
Dutch | 122.7 KB | ||
| 2021-04-13 07:00 |
210412 PR EGM_EGM_invitation_2021_ENG_FINAL.pdf
|
English | 156.6 KB | ||
| 2021-04-13 07:00 |
210412 PR EGM_EGM_invitation_2021_NL_FINAL.pdf
|
Dutch | 157.3 KB | ||
| 2021-04-01 07:00 |
Annex 4_Statutory Annual Report 2020.pdf
|
English | 1.1 MB | ||
| 2021-04-01 07:00 |
AR2020-Biocartis_Group-AuditReportSigned_NL.docx.pdf
|
Dutch | 569.6 KB | ||
| 2021-04-01 07:00 |
210330 AR2020_ENG_FULLVERSION_FINAL.pdf
|
English | 4.0 MB | ||
| 2021-04-01 07:00 |
Annex 3_Statutory Annual Accounts (Dutch only).pdf
|
Dutch | 329.7 KB | ||
| 2021-04-01 07:00 |
AR2020-Biocartis_Group-AuditReportSigned_ENG.docx.pdf
|
English | 572.3 KB | ||
| 2021-04-01 07:00 |
210330 AR2020_NL_FULLVERSION_FINAL.pdf
|
Dutch | 3.7 MB | ||
| 2021-04-01 07:00 |
210331 PR Annual report 2020_publication_ENG_FINAL.pdf
|
English | 148.2 KB | ||
| 2021-04-01 07:00 |
210331 PR Annual report 2020_publication_NL_FINAL.pdf
|
Dutch | 153.2 KB |
Automate Your Workflow. Get a real-time feed of all Biocartis Group NV filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biocartis Group NV
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biocartis Group NV via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-04-29 | Devogelaere Benoit | Executive member | Buy | 15,000 | N/A |
| 2021-04-28 | Marcofin BV | Executive member | Buy | 30,000 | N/A |
| 2021-04-27 | Herman Verrelst | Board | Buy | 60,000 | N/A |
| 2020-11-13 | Devogelaere Benoit | Executive member | Buy | 50,000 | N/A |
| 2020-05-06 | Herman Verrelst | Board | Buy | 50,000 | 249,625.00 EUR |
| 2020-05-06 | Herman Verrelst | Board | Buy | 300,000 | N/A |
| 2020-05-04 | Herman Verrelst | Board | Buy | 46,803 | 231,656.00 EUR |
| 2020-05-04 | Herman Verrelst | Board | Buy | 3,197 | 15,315.00 EUR |
| 2019-12-18 | Devogelaere Benoit | Executive member | Buy | 50,000 | N/A |
| 2019-12-16 | Welten Ewoud | Executive member | Buy | 10,000 | N/A |
Peer Companies
